Contributors: Tim Blackstock

Orexigen has made interim data from the LIGHT study publically available in a financial report; details can be viewed here. This ongoing cardiovascular outcomes trial (CVOT) is evaluating the safety of Contrave Orexigen and Takeda Pharmaceutical's recently launched fixed-dose combination of naltrexone and bupropion for treating obesity as there were concerns over the drug's effect on heart rate and blood pressure. Although interim results must be interpreted with caution, they are encouraging, as the graph of major adverse cardiovascular events (MACE) below illustrates:

 

Pivoting a product launch during the pandemic

View Now